María Alejandra GarcíaAlejandro Durán CraneEdgardo ChapmanElizabeth García2026-03-222026-03-22201910.29262/ram.v66i3.401https://doi.org/10.29262/ram.v66i3.401https://andeanlibrary.org/handle/123456789/50408Citaciones: 7Omalizumab appears promising for treating severe atopic dermatitis in pediatric patients. That results shows that omalizubam improves the quality of life, also decreases the severity of the disease and the need for systemic steroid and immunosuppressive therapy, which decreases the side effects that are caused by these medications.enMedicineAtopic dermatitisOmalizumabSCORADQuality of life (healthcare)Dermatology Life Quality IndexDermatologyDiseaseAdjuvant therapyAllergyarticle